文献速递妇科

FIGO 2023 IIC期子宫内膜癌辅助放疗结局与预后因素:同一海洋,不同深度

Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
PubMed 文献 · Gynecol Oncol · 2025-06-17

本研究回顾性分析1994至2023年间1297例术后接受辅助放疗的子宫内膜癌患者,其中229例符合FIGO 2023 IIC期标准。中位随访64.5个月,局部区域控制率95%,5年总生存率88%、无进展生存率82%;高龄和宫颈管间质浸润为不良预后因素,化疗仅对非子宫内膜样肿瘤有生存获益。

要点

  • FIGO 2023 IIC期子宫内膜癌异质性大,辅助放疗局部区域控制率达95%,远处转移仍是主要挑战。
  • 高龄(≥60岁)与更差的总生存(HR 5.9)和无进展生存(HR 7.1)相关。
  • 宫颈管间质浸润独立预测更差的无进展生存(HR 2.79),化疗获益仅见于非子宫内膜样肿瘤。

核心结论

  • FIGO 2023 IIC期子宫内膜癌结局多样,辅助放疗提供出色的局部区域控制,但远处转移仍具挑战性。
  • 宫颈管间质浸润是预测更差无进展生存的关键预后因素,化疗仅对非子宫内膜样肿瘤显示获益。
  • 这些发现强调了个体化风险分组和辅助治疗策略的迫切需要。

研究设计与样本

  • 回顾性评估1994年至2023年间接受手术分期后辅助放疗的1297例子宫内膜癌患者。
  • 其中229例符合FIGO 2023 IIC期标准并纳入本研究。

主要发现

  • 队列包括59%高级别子宫内膜样癌和41%非子宫内膜样癌。
  • 阴道近距离放疗是主要放疗方式(63%),38%接受化疗联合放疗。
  • 中位随访64.5个月,复发率14%,主要为远处转移,局部区域控制率95%。
  • 5年总生存率和无进展生存率分别为88%和82%。
  • 高龄(≥60岁)预测更差的总生存(HR 5.9,p < 0.001)和无进展生存(HR 7.1,p < 0.001),宫颈管间质浸润独立与更差的无进展生存相关(HR 2.79,p = 0.003)。

临床怎么用

  • 作者认为这些发现强调了个体化风险分组和辅助治疗策略的迫切需要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: FIGO 2023 Stage IIC endometrial cancer (EC) comprises a heterogeneous group of uterine-confined, myoinvasive tumors with aggressive histological subtypes. This study aimed to evaluate treatment outcomes and identify prognostic factors in patients treated with adjuvant radiotherapy (RT), with or without chemotherapy (CTX). METHODS: A retrospective evaluation was conducted on 1297 EC patients treated with adjuvant RT following surgical staging between 1994 and 2023. Among these, 229 patients met the FIGO 2023 Stage IIC criteria and were included in this study. RESULTS: The cohort included 59 % high-grade endometrioid and 41 % non-endometrioid EC. Vaginal brachytherapy was the primary RT modality (63 %), with 38 % receiving combined CTX and RT. Over a median follow-up of 64.5 months, recurrences occurred in 14 %, primarily as distant metastases (DM), while locoregional control (LRC) was 95 %. Five-year overall survival (OS) and progression-free survival (PFS) rates were 88 % and 82 %, respectively. Advanced age (≥ 60 years) predicted worse OS (HR: 5.9, p < 0.001) and PFS (HR: 7.1, p < 0.001), and endocervical stromal invasion was independently associated with worse PFS (HR: 2.79, p = 0.003). CTX improved OS and PFS in non-endometrioid tumors but showed no benefit in high-grade endometrioid cancer. CONCLUSIONS: Although FIGO 2023 Stage IIC EC shows diverse outcomes, adjuvant RT provides excellent LRC, while DM remain challenging. Endocervical stromal invasion remains a key prognostic factor, predicting poorer PFS, while CTX shows benefit exclusively in non-endometrioid tumors. These findings emphasize the critical need for personalized risk-grouping and adjuvant treatment strategies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kahvecioglu A, Gultekin M, Yigit E, et al. Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths. Gynecol Oncol. 2025. PMID: 40532615. doi:10.1016/j.ygyno.2025.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。